<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964313</url>
  </required_header>
  <id_info>
    <org_study_id>2011BAI11B06</org_study_id>
    <nct_id>NCT01964313</nct_id>
  </id_info>
  <brief_title>Acute Coronary Syndrome Genetic Study</brief_title>
  <official_title>Comprehensive Intervention and Outcome Research Programs for Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the role of genetic factors and its relationship and interaction with&#xD;
      environmental factors in the recurrence of cardiac events in Chinese patients with acute&#xD;
      coronary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Research cohort: Patients diagnosed with acute coronary syndrome are enrolled and to be&#xD;
           followed up for 2 years.&#xD;
&#xD;
        -  Baseline and follow up variables include patients' demographics, medical history, ACS&#xD;
           event characteristics, clinical treatment options (interventional cardiology, drug&#xD;
           therapy: antithrombotic therapy, other treatments recommended by guidelines ) and follow&#xD;
           up events information.&#xD;
&#xD;
        -  Blood Sample collection 4ml of vein blood will be drawed. Centrifugation of plasma and&#xD;
           WBC will be done on-site within 30 minutes for DNA extraction. Samples will be stored at&#xD;
           -80℃ freezer for subsequent applications.&#xD;
&#xD;
        -  A nested case-controlled study is designed for the genetic analysis:&#xD;
&#xD;
             1. Cases: Patients suffered from death, myocardial infarction, stroke and coronary&#xD;
                revascularization and bleeding during the 2-year follow up. We expected to get 600&#xD;
                cases in the study cohort;&#xD;
&#xD;
             2. Controls: among patients without any of the above events during follow, matched&#xD;
                controls of 1:1 ratio will be selected according to date of admission (± 1 month),&#xD;
                age (± 5 years), sex, baseline ACS diagnosis, whether treated with PCI , the same&#xD;
                pattern of antithrombotic therapy and the study center.&#xD;
&#xD;
        -  Genotyping Genotype testing using exome DNA chips (Exome Beadchip). Exome Beadchip is a&#xD;
           high-throughput DNA chip designed by Illumina's, containing 240,000 SNP on exons in the&#xD;
           genome that may lead to functional changes.&#xD;
&#xD;
        -  Analysis:&#xD;
&#xD;
             1. To analysis the impact of genetic characteristics on selection of treatment&#xD;
                strategy in ACS patients, and its interaction with other baseline clinical&#xD;
                variables.&#xD;
&#xD;
             2. To analysis the impact of genetic characteristics on patient outcomes, and its&#xD;
                interaction with clinical characteristics and management patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>2 year</time_frame>
    <description>Death, Myocardial infarction, stroke, coronary revascularization</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3422</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>ACS cohort</arm_group_label>
    <description>Patients diagnosed with acute coronary syndrome.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4ml of vein blood are to be retained for genetic analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 75 hospitals in China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent has been provided.&#xD;
&#xD;
          -  Contact Order Form has been provided.&#xD;
&#xD;
          -  Aged 18 years or older.&#xD;
&#xD;
          -  Diagnosis of STEMI, NSTEMI or UA using the following definitions:&#xD;
&#xD;
               1. Criteria for STEMI diagnosis:&#xD;
&#xD;
                    1. History of chest pain/discomfort and&#xD;
&#xD;
                    2. Persistent ST-segment elevation (&gt; 30 min) of ≥ 0.1 mV in 2 or more&#xD;
                       contiguous ECG leads or presumed new left bundle branch block (LBBB) on&#xD;
                       admission and&#xD;
&#xD;
                    3. Elevation of cardiac biomarkers (CK-MB, troponins): at least one value above&#xD;
                       the 99th percentile of the local laboratory upper reference limit.&#xD;
&#xD;
               2. Criteria for NSTEMI diagnosis:&#xD;
&#xD;
                    1. History of chest pain/discomfort and&#xD;
&#xD;
                    2. Lack of persistent ST-segment elevation, LBBB or intraventricular conduction&#xD;
                       disturbances and&#xD;
&#xD;
                    3. Elevation of cardiac biomarkers (CK-MB, troponins): at least one value above&#xD;
                       the 99th percentile of the local laboratory upper reference limit.&#xD;
&#xD;
               3. Criteria for Unstable Angina diagnosis:&#xD;
&#xD;
                    1. Symptoms of angina at rest or on minimal exercise and&#xD;
&#xD;
                    2. At least 0.5mm ST deviation in at least 2 leads and&#xD;
&#xD;
                    3. No increase in biomarkers of necrosis&#xD;
&#xD;
                    4. OR objective evidence of ischaemia by non-invasive imaging OR significant&#xD;
                       coronary stenosis as determined by the treating physician at angiography if&#xD;
                       this is standard practice in study site.&#xD;
&#xD;
          -  Hospitalized within 48 hours of onset of symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will not be eligible to participate if any of the following exclusion criteria are&#xD;
        present:&#xD;
&#xD;
          -  UA, STEMI and NSTEMI precipitated by or as a complication of surgery, trauma, or GI&#xD;
             bleeding or post-PCI.&#xD;
&#xD;
          -  UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.&#xD;
&#xD;
          -  Presence of any condition/circumstance which in the opinion of the investigator could&#xD;
             significantly limit the complete follow up of the patient (e.g. tourist, non-native&#xD;
             speaker or does not understand the local language, psychiatric disturbances).&#xD;
&#xD;
          -  Presence of serious/severe co-morbidities in the opinion of the investigator which may&#xD;
             limit short term (i.e. 6 month) life expectancy.&#xD;
&#xD;
          -  Current participation in a randomised interventional clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Jiang, MD</last_name>
    <phone>8610-83575180</phone>
    <email>jiangjie@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaolan Zhou</last_name>
    <phone>8610-83575262</phone>
    <email>zhouxiaolan@clevel.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jiang</last_name>
    </contact>
    <investigator>
      <last_name>Jie Jiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Yong Huo</investigator_full_name>
    <investigator_title>Director, Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>treatment strategy</keyword>
  <keyword>genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

